Entries by fswpadmin

Affigen and CCRM Announce Partnership to Develop Personalized Therapeutics

Sept. 29, 2017 (TORONTO and ST. LOUIS) — CCRM, a leader in the development and commercialization of regenerative medicine technologies, cell and gene therapies and Affigen, a biotechnology company that is developing therapeutics that target cell lineage-specific tumor proteins, are pleased to announce a new partnership that will advance the creation and commercialization of a […]

Affigen Announces $17 million Series A Led by Black Beret Life Sciences

Funding for Development of Cancer Immunotherapies Targeting Cell Lineage-Specific Tumor Proteins Feb. 21, 2017 (ST. LOUIS and HOUSTON) — Affigen, a biotechnology company that develops therapeutics targeting cell lineage-specific tumor proteins, today announced the closing of a $17 million Series A financing round led by Black Beret Life Sciences on behalf of its affiliate BBLS […]

Affigen is Hiring!

We’re hiring!  Affigen has several open positions, and we’re looking for talented individuals across all areas of the company to help us achieve our goals.